nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—urinary bladder cancer—testicular cancer	0.163	0.304	CtDrD
Methotrexate—muscle cancer—testicular cancer	0.138	0.257	CtDrD
Methotrexate—germ cell cancer—testicular cancer	0.124	0.231	CtDrD
Methotrexate—lung cancer—testicular cancer	0.112	0.208	CtDrD
Methotrexate—SLCO1A2—Chlorambucil—testicular cancer	0.0371	0.123	CbGbCtD
Methotrexate—ABCC10—Etoposide—testicular cancer	0.0292	0.0969	CbGbCtD
Methotrexate—ABCC1—Dactinomycin—testicular cancer	0.02	0.0663	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—testicular cancer	0.0199	0.0661	CbGbCtD
Methotrexate—ABCC3—Cisplatin—testicular cancer	0.0187	0.062	CbGbCtD
Methotrexate—ABCC3—Etoposide—testicular cancer	0.0184	0.0609	CbGbCtD
Methotrexate—ABCC1—Epirubicin—testicular cancer	0.0145	0.048	CbGbCtD
Methotrexate—ABCG2—Dactinomycin—testicular cancer	0.0134	0.0444	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—testicular cancer	0.0125	0.0416	CbGbCtD
Methotrexate—ABCC1—Vinblastine—testicular cancer	0.0125	0.0415	CbGbCtD
Methotrexate—ABCC1—Etoposide—testicular cancer	0.0113	0.0374	CbGbCtD
Methotrexate—ABCC2—Carboplatin—testicular cancer	0.00994	0.033	CbGbCtD
Methotrexate—ABCC2—Vinblastine—testicular cancer	0.00927	0.0307	CbGbCtD
Methotrexate—ABCG2—Carboplatin—testicular cancer	0.00899	0.0298	CbGbCtD
Methotrexate—ABCC2—Cisplatin—testicular cancer	0.0085	0.0282	CbGbCtD
Methotrexate—ABCC2—Etoposide—testicular cancer	0.00835	0.0277	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—testicular cancer	0.00769	0.0255	CbGbCtD
Methotrexate—ABCG2—Cisplatin—testicular cancer	0.00768	0.0255	CbGbCtD
Methotrexate—ABCG2—Etoposide—testicular cancer	0.00755	0.025	CbGbCtD
Methotrexate—ABCC2—Doxorubicin—testicular cancer	0.00569	0.0189	CbGbCtD
Methotrexate—ABCG2—Doxorubicin—testicular cancer	0.00515	0.0171	CbGbCtD
Methotrexate—ABCB1—Dactinomycin—testicular cancer	0.00482	0.016	CbGbCtD
Methotrexate—ABCB1—Vinblastine—testicular cancer	0.00302	0.01	CbGbCtD
Methotrexate—ABCB1—Cisplatin—testicular cancer	0.00277	0.00919	CbGbCtD
Methotrexate—ABCB1—Etoposide—testicular cancer	0.00272	0.00903	CbGbCtD
Methotrexate—ABCB1—Doxorubicin—testicular cancer	0.00186	0.00616	CbGbCtD
Methotrexate—ABCC11—embryo—testicular cancer	0.00165	0.0402	CbGeAlD
Methotrexate—FOLR1—seminal vesicle—testicular cancer	0.00161	0.0394	CbGeAlD
Methotrexate—ABCC11—gonad—testicular cancer	0.00112	0.0273	CbGeAlD
Methotrexate—SLC46A1—seminal vesicle—testicular cancer	0.00109	0.0266	CbGeAlD
Methotrexate—GGH—seminal vesicle—testicular cancer	0.00107	0.0262	CbGeAlD
Methotrexate—MTHFR—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.00106	0.0743	CbGpPWpGaD
Methotrexate—SLC19A1—gonad—testicular cancer	0.00102	0.025	CbGeAlD
Methotrexate—ATIC—embryo—testicular cancer	0.00097	0.0237	CbGeAlD
Methotrexate—SLCO4C1—seminal vesicle—testicular cancer	0.000951	0.0232	CbGeAlD
Methotrexate—FOLR1—female gonad—testicular cancer	0.000947	0.0232	CbGeAlD
Methotrexate—DHFR—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.000946	0.066	CbGpPWpGaD
Methotrexate—FPGS—seminal vesicle—testicular cancer	0.000942	0.023	CbGeAlD
Methotrexate—ABCC11—female gonad—testicular cancer	0.000908	0.0222	CbGeAlD
Methotrexate—TYMS—Trans-sulfuration and one carbon metabolism—DNMT3L—testicular cancer	0.000826	0.0576	CbGpPWpGaD
Methotrexate—ABCC11—testis—testicular cancer	0.000805	0.0197	CbGeAlD
Methotrexate—GGH—gonad—testicular cancer	0.000775	0.0189	CbGeAlD
Methotrexate—SLC19A1—testis—testicular cancer	0.000737	0.018	CbGeAlD
Methotrexate—SLCO3A1—seminal vesicle—testicular cancer	0.000667	0.0163	CbGeAlD
Methotrexate—ATIC—gonad—testicular cancer	0.000659	0.0161	CbGeAlD
Methotrexate—DHFR—embryo—testicular cancer	0.000652	0.0159	CbGeAlD
Methotrexate—SLC46A1—female gonad—testicular cancer	0.00064	0.0156	CbGeAlD
Methotrexate—PGD—NRF2 pathway—SLC2A6—testicular cancer	0.000632	0.0441	CbGpPWpGaD
Methotrexate—GGH—female gonad—testicular cancer	0.000629	0.0154	CbGeAlD
Methotrexate—DHFR—seminal vesicle—testicular cancer	0.000612	0.015	CbGeAlD
Methotrexate—PGD—seminal vesicle—testicular cancer	0.000588	0.0144	CbGeAlD
Methotrexate—SLC46A1—testis—testicular cancer	0.000567	0.0139	CbGeAlD
Methotrexate—GGH—testis—testicular cancer	0.000558	0.0136	CbGeAlD
Methotrexate—FPGS—female gonad—testicular cancer	0.000553	0.0135	CbGeAlD
Methotrexate—ATIC—female gonad—testicular cancer	0.000535	0.0131	CbGeAlD
Methotrexate—SLC19A1—lymph node—testicular cancer	0.000534	0.0131	CbGeAlD
Methotrexate—AOX1—seminal vesicle—testicular cancer	0.000518	0.0127	CbGeAlD
Methotrexate—ABCC10—seminal vesicle—testicular cancer	0.000505	0.0123	CbGeAlD
Methotrexate—FPGS—testis—testicular cancer	0.000491	0.012	CbGeAlD
Methotrexate—SLCO3A1—gonad—testicular cancer	0.000482	0.0118	CbGeAlD
Methotrexate—SLC22A11—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000477	0.0333	CbGpPWpGaD
Methotrexate—ATIC—testis—testicular cancer	0.000475	0.0116	CbGeAlD
Methotrexate—SLC16A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000468	0.0327	CbGpPWpGaD
Methotrexate—TYMS—gonad—testicular cancer	0.000447	0.0109	CbGeAlD
Methotrexate—DHFR—gonad—testicular cancer	0.000442	0.0108	CbGeAlD
Methotrexate—SLC22A7—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000433	0.0302	CbGpPWpGaD
Methotrexate—PGD—gonad—testicular cancer	0.000425	0.0104	CbGeAlD
Methotrexate—SLCO3A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000413	0.0288	CbGpPWpGaD
Methotrexate—SLC46A1—lymph node—testicular cancer	0.000411	0.0101	CbGeAlD
Methotrexate—GGH—lymph node—testicular cancer	0.000405	0.00989	CbGeAlD
Methotrexate—MTHFR—female gonad—testicular cancer	0.000398	0.00972	CbGeAlD
Methotrexate—SLC16A1—gonad—testicular cancer	0.000397	0.0097	CbGeAlD
Methotrexate—SLCO1C1—testis—testicular cancer	0.000395	0.00965	CbGeAlD
Methotrexate—SLCO4C1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000394	0.0275	CbGpPWpGaD
Methotrexate—SLCO3A1—female gonad—testicular cancer	0.000391	0.00957	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—testicular cancer	0.000387	0.35	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—testicular cancer	0.000386	0.35	CbGdCrCtD
Methotrexate—AOX1—gonad—testicular cancer	0.000375	0.00916	CbGeAlD
Methotrexate—SLC22A7—testis—testicular cancer	0.000374	0.00915	CbGeAlD
Methotrexate—ABCC10—gonad—testicular cancer	0.000365	0.00891	CbGeAlD
Methotrexate—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000364	0.0254	CbGpPWpGaD
Methotrexate—TYMS—female gonad—testicular cancer	0.000363	0.00887	CbGeAlD
Methotrexate—DHFR—female gonad—testicular cancer	0.000359	0.00878	CbGeAlD
Methotrexate—ABCC1—seminal vesicle—testicular cancer	0.000357	0.00872	CbGeAlD
Methotrexate—FPGS—lymph node—testicular cancer	0.000356	0.0087	CbGeAlD
Methotrexate—MTHFR—testis—testicular cancer	0.000353	0.00862	CbGeAlD
Methotrexate—SLCO3A1—testis—testicular cancer	0.000347	0.00849	CbGeAlD
Methotrexate—PGD—female gonad—testicular cancer	0.000346	0.00845	CbGeAlD
Methotrexate—ATIC—lymph node—testicular cancer	0.000344	0.00841	CbGeAlD
Methotrexate—ABCC11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000334	0.0233	CbGpPWpGaD
Methotrexate—TYMS—Vincristine—Vinblastine—testicular cancer	0.000331	0.3	CbGdCrCtD
Methotrexate—SLCO1C1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.00033	0.023	CbGpPWpGaD
Methotrexate—SLC16A1—female gonad—testicular cancer	0.000323	0.00788	CbGeAlD
Methotrexate—TYMS—testis—testicular cancer	0.000322	0.00787	CbGeAlD
Methotrexate—DHFR—testis—testicular cancer	0.000319	0.00779	CbGeAlD
Methotrexate—PGD—testis—testicular cancer	0.000306	0.00749	CbGeAlD
Methotrexate—AOX1—female gonad—testicular cancer	0.000304	0.00744	CbGeAlD
Methotrexate—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000304	0.0212	CbGpPWpGaD
Methotrexate—ABCC3—female gonad—testicular cancer	0.000298	0.00728	CbGeAlD
Methotrexate—ABCC10—female gonad—testicular cancer	0.000296	0.00724	CbGeAlD
Methotrexate—ABCG2—seminal vesicle—testicular cancer	0.000295	0.00722	CbGeAlD
Methotrexate—ABCC4—Ectoderm Differentiation—TFAP2C—testicular cancer	0.000288	0.0201	CbGpPWpGaD
Methotrexate—SLC16A1—testis—testicular cancer	0.000286	0.00699	CbGeAlD
Methotrexate—SLCO1C1—lymph node—testicular cancer	0.000286	0.00699	CbGeAlD
Methotrexate—AOX1—testis—testicular cancer	0.00027	0.0066	CbGeAlD
Methotrexate—ABCC3—NRF2 pathway—SLC2A6—testicular cancer	0.000268	0.0187	CbGpPWpGaD
Methotrexate—ABCC3—testis—testicular cancer	0.000264	0.00645	CbGeAlD
Methotrexate—ABCC10—testis—testicular cancer	0.000263	0.00642	CbGeAlD
Methotrexate—MTHFR—lymph node—testicular cancer	0.000256	0.00625	CbGeAlD
Methotrexate—ABCC4—NRF2 pathway—SLC2A6—testicular cancer	0.000252	0.0176	CbGpPWpGaD
Methotrexate—SLCO3A1—lymph node—testicular cancer	0.000252	0.00615	CbGeAlD
Methotrexate—ABCC4—female gonad—testicular cancer	0.000246	0.00601	CbGeAlD
Methotrexate—TYMS—lymph node—testicular cancer	0.000233	0.0057	CbGeAlD
Methotrexate—DHFR—lymph node—testicular cancer	0.000231	0.00565	CbGeAlD
Methotrexate—SLCO1A2—testis—testicular cancer	0.000226	0.00554	CbGeAlD
Methotrexate—ALB—testis—testicular cancer	0.000225	0.0055	CbGeAlD
Methotrexate—PGD—lymph node—testicular cancer	0.000222	0.00543	CbGeAlD
Methotrexate—SLC46A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000221	0.0154	CbGpPWpGaD
Methotrexate—ABCC10—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000221	0.0154	CbGpPWpGaD
Methotrexate—ABCC4—testis—testicular cancer	0.000218	0.00533	CbGeAlD
Methotrexate—SLC22A11—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000217	0.0151	CbGpPWpGaD
Methotrexate—SLC16A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000213	0.0148	CbGpPWpGaD
Methotrexate—ABCC2—NRF2 pathway—SLC2A6—testicular cancer	0.000212	0.0148	CbGpPWpGaD
Methotrexate—ABCC2—testis—testicular cancer	0.000211	0.00516	CbGeAlD
Methotrexate—SLCO3A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00021	0.0146	CbGpPWpGaD
Methotrexate—ABCC1—female gonad—testicular cancer	0.00021	0.00512	CbGeAlD
Methotrexate—SLC16A1—lymph node—testicular cancer	0.000207	0.00507	CbGeAlD
Methotrexate—SLCO4C1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0002	0.014	CbGpPWpGaD
Methotrexate—SLC22A7—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000197	0.0137	CbGpPWpGaD
Methotrexate—AOX1—lymph node—testicular cancer	0.000196	0.00478	CbGeAlD
Methotrexate—ABCC3—lymph node—testicular cancer	0.000191	0.00468	CbGeAlD
Methotrexate—ABCC10—lymph node—testicular cancer	0.00019	0.00466	CbGeAlD
Methotrexate—SLCO1B3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000187	0.013	CbGpPWpGaD
Methotrexate—ABCC1—testis—testicular cancer	0.000186	0.00454	CbGeAlD
Methotrexate—ABCC1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000179	0.0125	CbGpPWpGaD
Methotrexate—ABCG2—female gonad—testicular cancer	0.000173	0.00424	CbGeAlD
Methotrexate—SLCO1C1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000168	0.0117	CbGpPWpGaD
Methotrexate—SLC22A8—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000165	0.0115	CbGpPWpGaD
Methotrexate—ALB—lymph node—testicular cancer	0.000163	0.00399	CbGeAlD
Methotrexate—ABCC4—lymph node—testicular cancer	0.000158	0.00386	CbGeAlD
Methotrexate—ABCB1—embryo—testicular cancer	0.000155	0.00379	CbGeAlD
Methotrexate—ABCG2—testis—testicular cancer	0.000154	0.00376	CbGeAlD
Methotrexate—ABCC2—lymph node—testicular cancer	0.000153	0.00374	CbGeAlD
Methotrexate—DHFR—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.000149	0.0104	CbGpPWpGaD
Methotrexate—SLCO1A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000147	0.0103	CbGpPWpGaD
Methotrexate—ABCB1—seminal vesicle—testicular cancer	0.000146	0.00356	CbGeAlD
Methotrexate—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000138	0.00964	CbGpPWpGaD
Methotrexate—ABCC1—lymph node—testicular cancer	0.000135	0.00329	CbGeAlD
Methotrexate—TYMS—Retinoblastoma (RB) in Cancer—H2AFZ—testicular cancer	0.00013	0.00906	CbGpPWpGaD
Methotrexate—SLCO1B1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000126	0.00877	CbGpPWpGaD
Methotrexate—ABCG2—lymph node—testicular cancer	0.000112	0.00273	CbGeAlD
Methotrexate—SLC22A11—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.00011	0.00769	CbGpPWpGaD
Methotrexate—SLC16A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000108	0.00754	CbGpPWpGaD
Methotrexate—ABCB1—gonad—testicular cancer	0.000105	0.00257	CbGeAlD
Methotrexate—SLC22A7—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.0001	0.00698	CbGpPWpGaD
Methotrexate—SLCO1B3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	9.5e-05	0.00663	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	9.47e-05	0.00661	CbGpPWpGaD
Methotrexate—ABCC3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.57e-05	0.00598	CbGpPWpGaD
Methotrexate—ABCB1—female gonad—testicular cancer	8.55e-05	0.00209	CbGeAlD
Methotrexate—SLC22A8—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.41e-05	0.00587	CbGpPWpGaD
Methotrexate—ABCC4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.06e-05	0.00562	CbGpPWpGaD
Methotrexate—ABCB1—testis—testicular cancer	7.59e-05	0.00185	CbGeAlD
Methotrexate—SLCO1A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.47e-05	0.00521	CbGpPWpGaD
Methotrexate—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	7.36e-05	0.00514	CbGpPWpGaD
Methotrexate—ALB—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	7.18e-05	0.00501	CbGpPWpGaD
Methotrexate—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	7.02e-05	0.0049	CbGpPWpGaD
Methotrexate—TYMS—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	6.88e-05	0.0048	CbGpPWpGaD
Methotrexate—ABCC2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.8e-05	0.00474	CbGpPWpGaD
Methotrexate—ABCC1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.72e-05	0.00469	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.38e-05	0.00445	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.91e-05	0.00412	CbGpPWpGaD
Methotrexate—SLC19A1—Metabolism—HPGDS—testicular cancer	5.68e-05	0.00396	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle, Mitotic—MAD1L1—testicular cancer	5.51e-05	0.00384	CbGpPWpGaD
Methotrexate—ABCB1—lymph node—testicular cancer	5.5e-05	0.00134	CbGeAlD
Methotrexate—SLC19A1—Disease—H2AFZ—testicular cancer	4.96e-05	0.00346	CbGpPWpGaD
Methotrexate—DHFR—Cell Cycle—MAD1L1—testicular cancer	4.92e-05	0.00344	CbGpPWpGaD
Methotrexate—FPGS—Metabolism—HPGDS—testicular cancer	4.83e-05	0.00337	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—HPGDS—testicular cancer	4.83e-05	0.00337	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle, Mitotic—MAD1L1—testicular cancer	4.81e-05	0.00335	CbGpPWpGaD
Methotrexate—SLC19A1—Disease—KITLG—testicular cancer	4.56e-05	0.00318	CbGpPWpGaD
Methotrexate—Hypersensitivity—Dactinomycin—testicular cancer	4.37e-05	0.00042	CcSEcCtD
Methotrexate—Confusional state—Etoposide—testicular cancer	4.33e-05	0.000416	CcSEcCtD
Methotrexate—Urticaria—Ifosfamide—testicular cancer	4.32e-05	0.000415	CcSEcCtD
Methotrexate—Body temperature increased—Ifosfamide—testicular cancer	4.3e-05	0.000413	CcSEcCtD
Methotrexate—Abdominal pain—Ifosfamide—testicular cancer	4.3e-05	0.000413	CcSEcCtD
Methotrexate—TYMS—Cell Cycle—MAD1L1—testicular cancer	4.3e-05	0.003	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Etoposide—testicular cancer	4.3e-05	0.000413	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—testicular cancer	4.29e-05	0.000413	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cisplatin—testicular cancer	4.27e-05	0.000411	CcSEcCtD
Methotrexate—Infection—Etoposide—testicular cancer	4.27e-05	0.00041	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—testicular cancer	4.26e-05	0.00041	CcSEcCtD
Methotrexate—Asthenia—Dactinomycin—testicular cancer	4.26e-05	0.000409	CcSEcCtD
Methotrexate—Asthma—Epirubicin—testicular cancer	4.23e-05	0.000407	CcSEcCtD
Methotrexate—FPGS—Disease—H2AFZ—testicular cancer	4.22e-05	0.00294	CbGpPWpGaD
Methotrexate—Paraesthesia—Cisplatin—testicular cancer	4.21e-05	0.000405	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—testicular cancer	4.21e-05	0.000404	CcSEcCtD
Methotrexate—Eosinophilia—Epirubicin—testicular cancer	4.19e-05	0.000403	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—testicular cancer	4.18e-05	0.000402	CcSEcCtD
Methotrexate—Dyspnoea—Cisplatin—testicular cancer	4.18e-05	0.000402	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—testicular cancer	4.17e-05	0.000401	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—testicular cancer	4.15e-05	0.000399	CcSEcCtD
Methotrexate—Pancreatitis—Epirubicin—testicular cancer	4.15e-05	0.000399	CcSEcCtD
Methotrexate—SLC19A1—Metabolism—STK11—testicular cancer	4.13e-05	0.00288	CbGpPWpGaD
Methotrexate—Breast disorder—Doxorubicin—testicular cancer	4.1e-05	0.000394	CcSEcCtD
Methotrexate—Anorexia—Etoposide—testicular cancer	4.09e-05	0.000394	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	4.08e-05	0.000392	CcSEcCtD
Methotrexate—Decreased appetite—Cisplatin—testicular cancer	4.08e-05	0.000392	CcSEcCtD
Methotrexate—Diarrhoea—Dactinomycin—testicular cancer	4.06e-05	0.00039	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cisplatin—testicular cancer	4.05e-05	0.000389	CcSEcCtD
Methotrexate—Vomiting—Bleomycin—testicular cancer	4.05e-05	0.000389	CcSEcCtD
Methotrexate—Pancytopenia—Epirubicin—testicular cancer	4.02e-05	0.000387	CcSEcCtD
Methotrexate—Hypotension—Etoposide—testicular cancer	4.01e-05	0.000386	CcSEcCtD
Methotrexate—Rash—Bleomycin—testicular cancer	4.01e-05	0.000386	CcSEcCtD
Methotrexate—Pain—Cisplatin—testicular cancer	4.01e-05	0.000386	CcSEcCtD
Methotrexate—Dermatitis—Bleomycin—testicular cancer	4.01e-05	0.000385	CcSEcCtD
Methotrexate—Hypersensitivity—Ifosfamide—testicular cancer	4.01e-05	0.000385	CcSEcCtD
Methotrexate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.98e-05	0.00278	CbGpPWpGaD
Methotrexate—Neutropenia—Epirubicin—testicular cancer	3.96e-05	0.000381	CcSEcCtD
Methotrexate—Dysuria—Epirubicin—testicular cancer	3.96e-05	0.000381	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Epirubicin—testicular cancer	3.93e-05	0.000378	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—testicular cancer	3.92e-05	0.000377	CcSEcCtD
Methotrexate—Asthenia—Ifosfamide—testicular cancer	3.9e-05	0.000375	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—testicular cancer	3.88e-05	0.000373	CcSEcCtD
Methotrexate—FPGS—Disease—KITLG—testicular cancer	3.88e-05	0.00271	CbGpPWpGaD
Methotrexate—Photosensitivity reaction—Epirubicin—testicular cancer	3.86e-05	0.000372	CcSEcCtD
Methotrexate—Feeling abnormal—Cisplatin—testicular cancer	3.86e-05	0.000372	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—testicular cancer	3.86e-05	0.000371	CcSEcCtD
Methotrexate—Pruritus—Ifosfamide—testicular cancer	3.85e-05	0.00037	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—testicular cancer	3.84e-05	0.000369	CcSEcCtD
Methotrexate—DHFR—Cell Cycle, Mitotic—H2AFZ—testicular cancer	3.84e-05	0.00268	CbGpPWpGaD
Methotrexate—Dyspnoea—Etoposide—testicular cancer	3.83e-05	0.000368	CcSEcCtD
Methotrexate—Somnolence—Etoposide—testicular cancer	3.82e-05	0.000367	CcSEcCtD
Methotrexate—Pneumonia—Epirubicin—testicular cancer	3.8e-05	0.000365	CcSEcCtD
Methotrexate—Nausea—Bleomycin—testicular cancer	3.78e-05	0.000363	CcSEcCtD
Methotrexate—Infestation NOS—Epirubicin—testicular cancer	3.78e-05	0.000363	CcSEcCtD
Methotrexate—Infestation—Epirubicin—testicular cancer	3.78e-05	0.000363	CcSEcCtD
Methotrexate—Drowsiness—Epirubicin—testicular cancer	3.78e-05	0.000363	CcSEcCtD
Methotrexate—Vomiting—Dactinomycin—testicular cancer	3.77e-05	0.000363	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—HPGDS—testicular cancer	3.76e-05	0.00263	CbGpPWpGaD
Methotrexate—Stevens-Johnson syndrome—Epirubicin—testicular cancer	3.74e-05	0.00036	CcSEcCtD
Methotrexate—Rash—Dactinomycin—testicular cancer	3.74e-05	0.00036	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—testicular cancer	3.73e-05	0.000359	CcSEcCtD
Methotrexate—Diarrhoea—Ifosfamide—testicular cancer	3.72e-05	0.000358	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—testicular cancer	3.72e-05	0.000358	CcSEcCtD
Methotrexate—Renal failure—Epirubicin—testicular cancer	3.71e-05	0.000357	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—testicular cancer	3.71e-05	0.000357	CcSEcCtD
Methotrexate—Body temperature increased—Cisplatin—testicular cancer	3.71e-05	0.000356	CcSEcCtD
Methotrexate—Fatigue—Etoposide—testicular cancer	3.7e-05	0.000356	CcSEcCtD
Methotrexate—Stomatitis—Epirubicin—testicular cancer	3.68e-05	0.000354	CcSEcCtD
Methotrexate—Pain—Etoposide—testicular cancer	3.67e-05	0.000353	CcSEcCtD
Methotrexate—Conjunctivitis—Epirubicin—testicular cancer	3.67e-05	0.000353	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—testicular cancer	3.66e-05	0.000352	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—testicular cancer	3.66e-05	0.000352	CcSEcCtD
Methotrexate—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.65e-05	0.00255	CbGpPWpGaD
Methotrexate—Upper respiratory tract infection—Doxorubicin—testicular cancer	3.64e-05	0.00035	CcSEcCtD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.63e-05	0.00253	CbGpPWpGaD
Methotrexate—Sweating—Epirubicin—testicular cancer	3.62e-05	0.000348	CcSEcCtD
Methotrexate—Haematuria—Epirubicin—testicular cancer	3.6e-05	0.000346	CcSEcCtD
Methotrexate—Dizziness—Ifosfamide—testicular cancer	3.6e-05	0.000346	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—testicular cancer	3.58e-05	0.000344	CcSEcCtD
Methotrexate—Hepatobiliary disease—Epirubicin—testicular cancer	3.57e-05	0.000343	CcSEcCtD
Methotrexate—Epistaxis—Epirubicin—testicular cancer	3.56e-05	0.000342	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—testicular cancer	3.54e-05	0.00034	CcSEcCtD
Methotrexate—Nausea—Dactinomycin—testicular cancer	3.53e-05	0.000339	CcSEcCtD
Methotrexate—Agranulocytosis—Epirubicin—testicular cancer	3.52e-05	0.000339	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—testicular cancer	3.51e-05	0.000338	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—testicular cancer	3.51e-05	0.000338	CcSEcCtD
Methotrexate—FPGS—Metabolism—STK11—testicular cancer	3.51e-05	0.00245	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—STK11—testicular cancer	3.51e-05	0.00245	CbGpPWpGaD
Methotrexate—Infestation—Doxorubicin—testicular cancer	3.49e-05	0.000336	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—testicular cancer	3.49e-05	0.000336	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—testicular cancer	3.49e-05	0.000336	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	3.46e-05	0.000333	CcSEcCtD
Methotrexate—Vomiting—Ifosfamide—testicular cancer	3.46e-05	0.000332	CcSEcCtD
Methotrexate—Hypersensitivity—Cisplatin—testicular cancer	3.45e-05	0.000332	CcSEcCtD
Methotrexate—PGD—Metabolism—HPGDS—testicular cancer	3.44e-05	0.0024	CbGpPWpGaD
Methotrexate—Renal failure—Doxorubicin—testicular cancer	3.43e-05	0.00033	CcSEcCtD
Methotrexate—DHFR—Cell Cycle—H2AFZ—testicular cancer	3.43e-05	0.0024	CbGpPWpGaD
Methotrexate—Rash—Ifosfamide—testicular cancer	3.43e-05	0.00033	CcSEcCtD
Methotrexate—Dermatitis—Ifosfamide—testicular cancer	3.43e-05	0.000329	CcSEcCtD
Methotrexate—Urticaria—Etoposide—testicular cancer	3.41e-05	0.000328	CcSEcCtD
Methotrexate—Haemoglobin—Epirubicin—testicular cancer	3.41e-05	0.000328	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—testicular cancer	3.4e-05	0.000327	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—testicular cancer	3.4e-05	0.000327	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—testicular cancer	3.4e-05	0.000327	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—testicular cancer	3.4e-05	0.000326	CcSEcCtD
Methotrexate—SLC19A1—Disease—FGFR3—testicular cancer	3.39e-05	0.00237	CbGpPWpGaD
Methotrexate—Hepatitis—Epirubicin—testicular cancer	3.39e-05	0.000326	CcSEcCtD
Methotrexate—Haemorrhage—Epirubicin—testicular cancer	3.39e-05	0.000326	CcSEcCtD
Methotrexate—Asthenia—Cisplatin—testicular cancer	3.36e-05	0.000323	CcSEcCtD
Methotrexate—Pharyngitis—Epirubicin—testicular cancer	3.36e-05	0.000323	CcSEcCtD
Methotrexate—TYMS—Cell Cycle, Mitotic—H2AFZ—testicular cancer	3.35e-05	0.00234	CbGpPWpGaD
Methotrexate—Sweating—Doxorubicin—testicular cancer	3.35e-05	0.000322	CcSEcCtD
Methotrexate—Urinary tract disorder—Epirubicin—testicular cancer	3.35e-05	0.000322	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—testicular cancer	3.33e-05	0.00032	CcSEcCtD
Methotrexate—Urethral disorder—Epirubicin—testicular cancer	3.32e-05	0.000319	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—testicular cancer	3.3e-05	0.000318	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—testicular cancer	3.29e-05	0.000317	CcSEcCtD
Methotrexate—SLC46A1—Disease—H2AFZ—testicular cancer	3.28e-05	0.00229	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	3.27e-05	0.00228	CbGpPWpGaD
Methotrexate—Visual impairment—Epirubicin—testicular cancer	3.27e-05	0.000314	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—testicular cancer	3.26e-05	0.000313	CcSEcCtD
Methotrexate—Nausea—Ifosfamide—testicular cancer	3.23e-05	0.000311	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—testicular cancer	3.21e-05	0.000308	CcSEcCtD
Methotrexate—Erythema multiforme—Epirubicin—testicular cancer	3.2e-05	0.000308	CcSEcCtD
Methotrexate—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.2e-05	0.00223	CbGpPWpGaD
Methotrexate—Eye disorder—Epirubicin—testicular cancer	3.17e-05	0.000305	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—testicular cancer	3.16e-05	0.000304	CcSEcCtD
Methotrexate—Tinnitus—Epirubicin—testicular cancer	3.16e-05	0.000304	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—testicular cancer	3.15e-05	0.000303	CcSEcCtD
Methotrexate—Cardiac disorder—Epirubicin—testicular cancer	3.15e-05	0.000302	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—testicular cancer	3.14e-05	0.000302	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—testicular cancer	3.14e-05	0.000302	CcSEcCtD
Methotrexate—SLC19A1—Disease—KIT—testicular cancer	3.11e-05	0.00217	CbGpPWpGaD
Methotrexate—Pharyngitis—Doxorubicin—testicular cancer	3.11e-05	0.000299	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—testicular cancer	3.1e-05	0.000298	CcSEcCtD
Methotrexate—Asthenia—Etoposide—testicular cancer	3.08e-05	0.000296	CcSEcCtD
Methotrexate—Angiopathy—Epirubicin—testicular cancer	3.07e-05	0.000296	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—testicular cancer	3.07e-05	0.000296	CcSEcCtD
Methotrexate—Immune system disorder—Epirubicin—testicular cancer	3.06e-05	0.000294	CcSEcCtD
Methotrexate—Mediastinal disorder—Epirubicin—testicular cancer	3.05e-05	0.000294	CcSEcCtD
Methotrexate—Chills—Epirubicin—testicular cancer	3.04e-05	0.000292	CcSEcCtD
Methotrexate—Pruritus—Etoposide—testicular cancer	3.04e-05	0.000292	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—testicular cancer	3.02e-05	0.000291	CcSEcCtD
Methotrexate—SLC46A1—Disease—KITLG—testicular cancer	3.02e-05	0.00211	CbGpPWpGaD
Methotrexate—PGD—Disease—H2AFZ—testicular cancer	3e-05	0.0021	CbGpPWpGaD
Methotrexate—TYMS—Cell Cycle—H2AFZ—testicular cancer	3e-05	0.00209	CbGpPWpGaD
Methotrexate—Alopecia—Epirubicin—testicular cancer	2.99e-05	0.000288	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—testicular cancer	2.98e-05	0.000287	CcSEcCtD
Methotrexate—Mental disorder—Epirubicin—testicular cancer	2.97e-05	0.000285	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—testicular cancer	2.96e-05	0.000285	CcSEcCtD
Methotrexate—Rash—Cisplatin—testicular cancer	2.96e-05	0.000284	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—testicular cancer	2.95e-05	0.000284	CcSEcCtD
Methotrexate—Erythema—Epirubicin—testicular cancer	2.95e-05	0.000284	CcSEcCtD
Methotrexate—Malnutrition—Epirubicin—testicular cancer	2.95e-05	0.000284	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—testicular cancer	2.94e-05	0.000283	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—testicular cancer	2.93e-05	0.000282	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—testicular cancer	2.92e-05	0.000281	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.92e-05	0.00204	CbGpPWpGaD
Methotrexate—Cardiac disorder—Doxorubicin—testicular cancer	2.91e-05	0.00028	CcSEcCtD
Methotrexate—Dysgeusia—Epirubicin—testicular cancer	2.89e-05	0.000278	CcSEcCtD
Methotrexate—FPGS—Disease—FGFR3—testicular cancer	2.88e-05	0.00201	CbGpPWpGaD
Methotrexate—Back pain—Epirubicin—testicular cancer	2.85e-05	0.000274	CcSEcCtD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.85e-05	0.00199	CbGpPWpGaD
Methotrexate—Angiopathy—Doxorubicin—testicular cancer	2.84e-05	0.000274	CcSEcCtD
Methotrexate—Dizziness—Etoposide—testicular cancer	2.84e-05	0.000273	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—testicular cancer	2.83e-05	0.000272	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—testicular cancer	2.83e-05	0.000272	CcSEcCtD
Methotrexate—Chills—Doxorubicin—testicular cancer	2.81e-05	0.000271	CcSEcCtD
Methotrexate—Nausea—Cisplatin—testicular cancer	2.78e-05	0.000268	CcSEcCtD
Methotrexate—Vision blurred—Epirubicin—testicular cancer	2.78e-05	0.000267	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—testicular cancer	2.77e-05	0.000266	CcSEcCtD
Methotrexate—PGD—Disease—KITLG—testicular cancer	2.76e-05	0.00193	CbGpPWpGaD
Methotrexate—Mental disorder—Doxorubicin—testicular cancer	2.75e-05	0.000264	CcSEcCtD
Methotrexate—Ill-defined disorder—Epirubicin—testicular cancer	2.74e-05	0.000263	CcSEcCtD
Methotrexate—SLC46A1—Metabolism—STK11—testicular cancer	2.73e-05	0.00191	CbGpPWpGaD
Methotrexate—Vomiting—Etoposide—testicular cancer	2.73e-05	0.000263	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—testicular cancer	2.73e-05	0.000262	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—testicular cancer	2.73e-05	0.000262	CcSEcCtD
Methotrexate—Anaemia—Epirubicin—testicular cancer	2.73e-05	0.000262	CcSEcCtD
Methotrexate—Rash—Etoposide—testicular cancer	2.71e-05	0.00026	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—testicular cancer	2.71e-05	0.00026	CcSEcCtD
Methotrexate—Headache—Etoposide—testicular cancer	2.69e-05	0.000259	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—testicular cancer	2.67e-05	0.000257	CcSEcCtD
Methotrexate—Malaise—Epirubicin—testicular cancer	2.66e-05	0.000256	CcSEcCtD
Methotrexate—Vertigo—Epirubicin—testicular cancer	2.65e-05	0.000255	CcSEcCtD
Methotrexate—FPGS—Disease—KIT—testicular cancer	2.65e-05	0.00185	CbGpPWpGaD
Methotrexate—Leukopenia—Epirubicin—testicular cancer	2.64e-05	0.000254	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—testicular cancer	2.64e-05	0.000254	CcSEcCtD
Methotrexate—Cough—Epirubicin—testicular cancer	2.57e-05	0.000248	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—testicular cancer	2.57e-05	0.000247	CcSEcCtD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.56e-05	0.00179	CbGpPWpGaD
Methotrexate—Convulsion—Epirubicin—testicular cancer	2.56e-05	0.000246	CcSEcCtD
Methotrexate—Nausea—Etoposide—testicular cancer	2.55e-05	0.000245	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—testicular cancer	2.53e-05	0.000244	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—testicular cancer	2.52e-05	0.000243	CcSEcCtD
Methotrexate—Chest pain—Epirubicin—testicular cancer	2.51e-05	0.000242	CcSEcCtD
Methotrexate—Arthralgia—Epirubicin—testicular cancer	2.51e-05	0.000242	CcSEcCtD
Methotrexate—Myalgia—Epirubicin—testicular cancer	2.51e-05	0.000242	CcSEcCtD
Methotrexate—PGD—Metabolism—STK11—testicular cancer	2.5e-05	0.00175	CbGpPWpGaD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	2.49e-05	0.00024	CcSEcCtD
Methotrexate—Discomfort—Epirubicin—testicular cancer	2.48e-05	0.000239	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—testicular cancer	2.46e-05	0.000237	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—testicular cancer	2.45e-05	0.000236	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—testicular cancer	2.44e-05	0.000235	CcSEcCtD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.44e-05	0.0017	CbGpPWpGaD
Methotrexate—Confusional state—Epirubicin—testicular cancer	2.43e-05	0.000233	CcSEcCtD
Methotrexate—Anaphylactic shock—Epirubicin—testicular cancer	2.41e-05	0.000232	CcSEcCtD
Methotrexate—Infection—Epirubicin—testicular cancer	2.39e-05	0.00023	CcSEcCtD
Methotrexate—Cough—Doxorubicin—testicular cancer	2.38e-05	0.000229	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—testicular cancer	2.37e-05	0.000227	CcSEcCtD
Methotrexate—Nervous system disorder—Epirubicin—testicular cancer	2.36e-05	0.000227	CcSEcCtD
Methotrexate—Thrombocytopenia—Epirubicin—testicular cancer	2.36e-05	0.000227	CcSEcCtD
Methotrexate—Skin disorder—Epirubicin—testicular cancer	2.34e-05	0.000225	CcSEcCtD
Methotrexate—Hyperhidrosis—Epirubicin—testicular cancer	2.33e-05	0.000224	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—testicular cancer	2.32e-05	0.000223	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—testicular cancer	2.32e-05	0.000223	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—testicular cancer	2.32e-05	0.000223	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.31e-05	0.000222	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—testicular cancer	2.3e-05	0.000221	CcSEcCtD
Methotrexate—Anorexia—Epirubicin—testicular cancer	2.3e-05	0.000221	CcSEcCtD
Methotrexate—MTHFR—Metabolism—HPGDS—testicular cancer	2.27e-05	0.00158	CbGpPWpGaD
Methotrexate—Hypotension—Epirubicin—testicular cancer	2.25e-05	0.000216	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—testicular cancer	2.25e-05	0.000216	CcSEcCtD
Methotrexate—SLC46A1—Disease—FGFR3—testicular cancer	2.25e-05	0.00157	CbGpPWpGaD
Methotrexate—Anaphylactic shock—Doxorubicin—testicular cancer	2.23e-05	0.000214	CcSEcCtD
Methotrexate—AOX1—Metabolism—HPGDS—testicular cancer	2.22e-05	0.00155	CbGpPWpGaD
Methotrexate—Infection—Doxorubicin—testicular cancer	2.21e-05	0.000213	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.19e-05	0.000211	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—testicular cancer	2.18e-05	0.00021	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—testicular cancer	2.18e-05	0.00021	CcSEcCtD
Methotrexate—Insomnia—Epirubicin—testicular cancer	2.18e-05	0.000209	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—testicular cancer	2.16e-05	0.000208	CcSEcCtD
Methotrexate—Paraesthesia—Epirubicin—testicular cancer	2.16e-05	0.000208	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—testicular cancer	2.15e-05	0.000207	CcSEcCtD
Methotrexate—Dyspnoea—Epirubicin—testicular cancer	2.15e-05	0.000206	CcSEcCtD
Methotrexate—Somnolence—Epirubicin—testicular cancer	2.14e-05	0.000206	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—testicular cancer	2.12e-05	0.000204	CcSEcCtD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.12e-05	0.00148	CbGpPWpGaD
Methotrexate—Dyspepsia—Epirubicin—testicular cancer	2.12e-05	0.000204	CcSEcCtD
Methotrexate—Decreased appetite—Epirubicin—testicular cancer	2.09e-05	0.000201	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—testicular cancer	2.08e-05	0.0002	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Epirubicin—testicular cancer	2.08e-05	0.0002	CcSEcCtD
Methotrexate—Fatigue—Epirubicin—testicular cancer	2.08e-05	0.0002	CcSEcCtD
Methotrexate—SLC46A1—Disease—KIT—testicular cancer	2.06e-05	0.00144	CbGpPWpGaD
Methotrexate—Pain—Epirubicin—testicular cancer	2.06e-05	0.000198	CcSEcCtD
Methotrexate—PGD—Disease—FGFR3—testicular cancer	2.05e-05	0.00143	CbGpPWpGaD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.03e-05	0.000195	CcSEcCtD
Methotrexate—DHFR—Metabolism—HPGDS—testicular cancer	2.02e-05	0.00141	CbGpPWpGaD
Methotrexate—Insomnia—Doxorubicin—testicular cancer	2.01e-05	0.000194	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—testicular cancer	2e-05	0.000192	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—testicular cancer	1.99e-05	0.000191	CcSEcCtD
Methotrexate—Feeling abnormal—Epirubicin—testicular cancer	1.98e-05	0.000191	CcSEcCtD
Methotrexate—MTHFR—Disease—H2AFZ—testicular cancer	1.98e-05	0.00138	CbGpPWpGaD
Methotrexate—Somnolence—Doxorubicin—testicular cancer	1.98e-05	0.00019	CcSEcCtD
Methotrexate—Gastrointestinal pain—Epirubicin—testicular cancer	1.97e-05	0.000189	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—testicular cancer	1.96e-05	0.000189	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—testicular cancer	1.94e-05	0.000186	CcSEcCtD
Methotrexate—AOX1—Disease—H2AFZ—testicular cancer	1.94e-05	0.00135	CbGpPWpGaD
Methotrexate—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.92e-05	0.000185	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—testicular cancer	1.92e-05	0.000185	CcSEcCtD
Methotrexate—Urticaria—Epirubicin—testicular cancer	1.91e-05	0.000184	CcSEcCtD
Methotrexate—Pain—Doxorubicin—testicular cancer	1.91e-05	0.000183	CcSEcCtD
Methotrexate—Body temperature increased—Epirubicin—testicular cancer	1.9e-05	0.000183	CcSEcCtD
Methotrexate—Abdominal pain—Epirubicin—testicular cancer	1.9e-05	0.000183	CcSEcCtD
Methotrexate—PGD—Disease—KIT—testicular cancer	1.89e-05	0.00132	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—HPGDS—testicular cancer	1.84e-05	0.00128	CbGpPWpGaD
Methotrexate—Feeling abnormal—Doxorubicin—testicular cancer	1.84e-05	0.000177	CcSEcCtD
Methotrexate—MTHFR—Disease—KITLG—testicular cancer	1.82e-05	0.00127	CbGpPWpGaD
Methotrexate—Gastrointestinal pain—Doxorubicin—testicular cancer	1.82e-05	0.000175	CcSEcCtD
Methotrexate—AOX1—Disease—KITLG—testicular cancer	1.78e-05	0.00124	CbGpPWpGaD
Methotrexate—Hypersensitivity—Epirubicin—testicular cancer	1.77e-05	0.000171	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—testicular cancer	1.77e-05	0.00017	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—testicular cancer	1.76e-05	0.000169	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—testicular cancer	1.76e-05	0.000169	CcSEcCtD
Methotrexate—DHFR—Disease—H2AFZ—testicular cancer	1.76e-05	0.00123	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—HPGDS—testicular cancer	1.76e-05	0.00123	CbGpPWpGaD
Methotrexate—Asthenia—Epirubicin—testicular cancer	1.73e-05	0.000166	CcSEcCtD
Methotrexate—Pruritus—Epirubicin—testicular cancer	1.7e-05	0.000164	CcSEcCtD
Methotrexate—MTHFR—Metabolism—STK11—testicular cancer	1.65e-05	0.00115	CbGpPWpGaD
Methotrexate—Diarrhoea—Epirubicin—testicular cancer	1.65e-05	0.000158	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—testicular cancer	1.64e-05	0.000158	CcSEcCtD
Methotrexate—DHFR—Disease—KITLG—testicular cancer	1.62e-05	0.00113	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—HPGDS—testicular cancer	1.62e-05	0.00113	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—STK11—testicular cancer	1.61e-05	0.00112	CbGpPWpGaD
Methotrexate—Asthenia—Doxorubicin—testicular cancer	1.6e-05	0.000154	CcSEcCtD
Methotrexate—Dizziness—Epirubicin—testicular cancer	1.59e-05	0.000153	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—testicular cancer	1.58e-05	0.000152	CcSEcCtD
Methotrexate—Vomiting—Epirubicin—testicular cancer	1.53e-05	0.000147	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—testicular cancer	1.52e-05	0.000147	CcSEcCtD
Methotrexate—Rash—Epirubicin—testicular cancer	1.52e-05	0.000146	CcSEcCtD
Methotrexate—Dermatitis—Epirubicin—testicular cancer	1.52e-05	0.000146	CcSEcCtD
Methotrexate—Headache—Epirubicin—testicular cancer	1.51e-05	0.000145	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—testicular cancer	1.47e-05	0.000142	CcSEcCtD
Methotrexate—DHFR—Metabolism—STK11—testicular cancer	1.47e-05	0.00102	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—HPGDS—testicular cancer	1.46e-05	0.00102	CbGpPWpGaD
Methotrexate—Nausea—Epirubicin—testicular cancer	1.43e-05	0.000138	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—testicular cancer	1.42e-05	0.000136	CcSEcCtD
Methotrexate—Rash—Doxorubicin—testicular cancer	1.4e-05	0.000135	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—testicular cancer	1.4e-05	0.000135	CcSEcCtD
Methotrexate—Headache—Doxorubicin—testicular cancer	1.4e-05	0.000134	CcSEcCtD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.39e-05	0.000972	CbGpPWpGaD
Methotrexate—MTHFR—Disease—FGFR3—testicular cancer	1.35e-05	0.000945	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—STK11—testicular cancer	1.34e-05	0.000932	CbGpPWpGaD
Methotrexate—AOX1—Disease—FGFR3—testicular cancer	1.32e-05	0.000923	CbGpPWpGaD
Methotrexate—Nausea—Doxorubicin—testicular cancer	1.32e-05	0.000127	CcSEcCtD
Methotrexate—TYMS—Metabolism—STK11—testicular cancer	1.28e-05	0.000893	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—HPGDS—testicular cancer	1.27e-05	0.000886	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KIT—testicular cancer	1.24e-05	0.000868	CbGpPWpGaD
Methotrexate—AOX1—Disease—KIT—testicular cancer	1.22e-05	0.000848	CbGpPWpGaD
Methotrexate—DHFR—Disease—FGFR3—testicular cancer	1.2e-05	0.00084	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—STK11—testicular cancer	1.17e-05	0.000819	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—HPGDS—testicular cancer	1.14e-05	0.000797	CbGpPWpGaD
Methotrexate—DHFR—Disease—KIT—testicular cancer	1.11e-05	0.000771	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—HPGDS—testicular cancer	1.09e-05	0.000757	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—STK11—testicular cancer	1.06e-05	0.000739	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—HPGDS—testicular cancer	1e-05	0.000701	CbGpPWpGaD
Methotrexate—ABCC1—Disease—H2AFZ—testicular cancer	9.97e-06	0.000695	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—STK11—testicular cancer	9.22e-06	0.000643	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KITLG—testicular cancer	9.17e-06	0.00064	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—STK11—testicular cancer	8.3e-06	0.000579	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—STK11—testicular cancer	7.89e-06	0.00055	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—STK11—testicular cancer	7.3e-06	0.000509	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR3—testicular cancer	6.81e-06	0.000475	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—testicular cancer	6.26e-06	0.000437	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGDS—testicular cancer	6.2e-06	0.000433	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGDS—testicular cancer	5.43e-06	0.000379	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STK11—testicular cancer	4.51e-06	0.000314	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STK11—testicular cancer	3.95e-06	0.000275	CbGpPWpGaD
